SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
Monster Beverage Corporation issued a press release on August 6, 2026, disclosing financial results for the second quarter ended June 30, 2026, with net sales of $2.54 billion (up 20.2%), net income of $584.5 million (up 19.6%), and diluted EPS of $0.59 (up 19.0%), along with detailed segment performance and six-month results.
View raw filing on EDGAR →The filing announces the scheduled release of United States Antimony Corporation's Second Quarter 2026 Financial and Operating Results on August 11, 2026, at 4:15 p.m. ET, with a conference call and webcast. This is a standard earnings announcement that would materially affect investor assessment of the company's financial performance and operational results.
View raw filing on EDGAR →This is a standard quarterly earnings release for Q2 2026 (quarter ended June 30, 2026) issued on August 6, 2026. The filing discloses total revenue of $40.1 million (vs. $2.1 million in Q2 2025), net product revenue of $25.1 million from AVMAPKI FAKZYNJA CO-PACK, and a net loss of $34.7 million. The press release is furnished as Exhibit 99.1 and incorporated into Item 2.02, which is the standard Item for results of operations and financial condition. Material to investors as it shows significant revenue growth from the newly commercialized product and cash position updates.
View raw filing on EDGAR →This press release announces Bit Origin's strategic deployment of 16 NVIDIA Blackwell B300 AI servers in Malaysia, scheduled for Q3 2026, supported by contracted customer demand and a five-year third-party management agreement. While the disclosure emphasizes market opportunity and operational structure rather than a discrete M&A transaction, the acquisition of servers with customer deployment arrangements and the establishment of a managed infrastructure operation constitute a material operational and strategic milestone for the company's AI computing infrastructure business. The event does not fit neatly into M&A (no merger or acquisition of another entity), but represents a significant operational commitment and capital deployment that would affect a reasonable investor's assessment of the company's execution and business model.
View raw filing on EDGAR →This is a clear earnings release disclosing Cryoport's Q2 2026 financial results. The Item 2.02 filing announces quarterly revenue of $49.0 million (8% YoY growth), gross margins, operating costs, and adjusted EBITDA of $0.4 million—a key milestone toward profitability. The press release is attached as Exhibit 99.1 and includes detailed financial tables, segment performance, and operational highlights, which is the standard format for earnings disclosures under Item 2.02.
View raw filing on EDGAR →The filing discloses the underwriters' exercise of an option to purchase an additional 2,250,000 shares of common stock in a registered public offering, generating approximately $312.2 million in net proceeds. This represents a dilutive equity issuance that increases shares outstanding and would materially affect a reasonable investor's assessment of ownership dilution and capital structure, even though it is a registered offering rather than a private placement.
View raw filing on EDGAR →Clearway Energy entered into an Equity Distribution Agreement (ATM Program) with major investment banks to offer and sell up to $100 million of Class C common stock at market prices. This at-the-market offering is a dilutive equity issuance to existing shareholders.
View raw filing on EDGAR →Clearway Energy, Inc. entered into an Equity Distribution Agreement (ATM Program) on August 6, 2026, authorizing the sale of up to $100 million in Class C common stock through multiple investment banks. This is a classic at-the-market (ATM) offering—an unregistered or registered equity issuance program that creates potential dilution to existing shareholders. The filing explicitly references the prospectus supplement and shelf registration statement (Form S-3), confirming this is a registered direct offering of equity securities. Such capital-raising activities are material to investors assessing the company's financing strategy and shareholder dilution risk.
View raw filing on EDGAR →DoubleVerify issued a press release on August 6, 2026 announcing financial results for Q2 and H1 2026, including revenue of $193.8 million (up 3% YoY), net income of $12.9 million, and adjusted EBITDA of $65.3 million. The Item 2.02 disclosure and attached Exhibit 99.1 press release are the standard format for earnings announcements. While the filing also mentions a pending merger with Nielsen, the primary disclosure under Item 2.02 is the quarterly financial results.
View raw filing on EDGAR →DoubleVerify announced entry into a definitive Agreement and Plan of Merger with Nielsen (via Neptune BidCo US Inc. and Wallace Merger Sub Inc.) on August 6, 2026. The transaction is valued at approximately $2.15 billion enterprise value with shareholders receiving $13.60 per share in cash (a 30% premium). This is a material acquisition/change of control requiring shareholder approval and regulatory clearance, expected to close by end of Q4 2026, with DoubleVerify becoming a privately held subsidiary of Nielsen.
View raw filing on EDGAR →Gerdau S.A. announces the completion of the acquisition of a 23.03% equity stake in Dona Francisca Energética S.A. (DFESA) from COPEL for R$150 million in cash. This is a material acquisition transaction that expands the company's renewable energy self-production capacity and is aligned with its decarbonization strategy, meeting the definition of ma_activity (completion of a material acquisition).
View raw filing on EDGAR →Aclaris entered into a Second Amended and Restated Sales Agreement (ATM Agreement) with Leerink and Cantor permitting the company to offer and sell shares of common stock "from time to time at the Company's sole discretion" through an at-the-market offering mechanism. This is a dilutive equity issuance arrangement that allows the company to raise capital by selling common stock to the public, which is material to investors as it signals potential capital needs and shareholder dilution.
View raw filing on EDGAR →Innodata entered into an equity distribution agreement with multiple sales agents to offer and sell up to $300 million in common stock shares through an "at the market offering" under a newly filed Form S-3 shelf registration. This is a dilutive equity issuance that creates potential for substantial shareholder dilution and capital raising, which materially affects investor assessment of the company's capital structure and financing strategy.
View raw filing on EDGAR →LTC Properties terminated its prior at-the-market equity distribution agreement and entered into a new Equity Distribution Agreement on August 6, 2026, permitting the issuance and sale of up to $500 million of common stock through sales agents and forward sale agreements. The company intends to use proceeds to pay down debt, fund acquisitions, and support working capital.
View raw filing on EDGAR →This Item 5.07 disclosure reports the results of the Company's Annual Meeting of Shareholders held on August 3, 2026, specifically the election of two Class I Trustees (Charles P. Pizzi and Pedro A. Ramos) for three-year terms. The filing provides vote tallies (votes for, against, withheld, and broker non-votes) for each nominee, which is the standard format for shareholder vote results. Board elections are material governance events affecting investor assessment of the registrant's leadership.
View raw filing on EDGAR →This is a clear disclosure of shareholder vote results from the Annual Meeting of Stockholders held on August 3, 2026. The filing reports voting outcomes for the Director Election Proposal, specifically the election of Walter W. Buckley, III as a Class I Director (123,713,305 votes for, 15,799,813 against, 1,547,474 withheld), and notes that voting on Barbara J. Fouss was adjourned due to lack of quorum among preferred stockholders. This is a quintessential Item 5.07 disclosure of shareholder meeting results.
View raw filing on EDGAR →The filing discloses Avient's second quarter 2026 financial results via a press release dated August 6, 2026. The press release reports Q2 2026 GAAP EPS of $0.70 (vs. $0.57 prior year), adjusted EPS of $0.96 (20% growth), sales growth of 5.8% to $917 million, and increased full-year 2026 adjusted EPS guidance to $3.10–$3.25 (10–15% growth). This is a standard earnings release disclosure under Item 2.02, material to investors assessing the company's financial performance and forward guidance.
View raw filing on EDGAR →nLIGHT announced its financial results for Q2 2026 on August 6, 2026, disclosing record revenues of $82.6 million (up 34% YoY), gross margin of 31.1%, and Adjusted EBITDA of $10.7 million. The full press release is furnished as Exhibit 99.1 and Item 2.02 explicitly states this is the announcement of financial results for the three and six months ended June 30, 2026. This is a standard quarterly earnings release with detailed financial statements and forward guidance.
View raw filing on EDGAR →This is a clear earnings release for Q2 2026 ended June 30, 2026. The filing discloses total company revenues of $425.5 million, product-specific revenues (BRINSUPRI $309.2M, ARIKAYCE $116.3M), operating expenses, net loss of $13.2 million, and balance sheet information. The company also raised full-year 2026 BRINSUPRI revenue guidance to $1.25-$1.40 billion and raised peak revenue estimates for its three lead programs to more than $14 billion combined. This is a material disclosure affecting investor assessment of the registrant's financial performance and outlook.
View raw filing on EDGAR →GH Research reported second quarter 2026 financial results, including a net loss of $15.1 million, cash position of $362.7 million, and detailed R&D and G&A expenses, along with condensed consolidated interim financial statements.
View raw filing on EDGAR →GH Research announced positive Phase 2b clinical trial results for GH001 (mebufotenin) in treatment-resistant depression, demonstrating primary efficacy endpoints (MADRS reduction of -15.5 vs placebo, P<0.0001) and remission rates of 57.5% at Day 8 and 73% at 6 months in open-label extension completers, with Phase 3 initiation planned for 2026.
View raw filing on EDGAR →This exhibit is a press release announcing InflaRx's second quarter 2026 financial results, including unaudited consolidated statements of operations, financial position, changes in shareholders' equity, and cash flows for the six months ended June 30, 2026. The document explicitly states "InflaRx Reports Second Quarter 2026 Results" and includes detailed financial highlights, net loss figures (€16.2 million for H1 2026), and cash position (€158.4 million). This is a discrete earnings announcement, not a periodic financial report filing itself.
View raw filing on EDGAR →This is a press release dated August 5, 2026, reporting Tronox's financial results for the second quarter ended June 30, 2026, attached as Exhibit 99.1 to the 8-K Item 2.02 filing. The disclosure includes detailed financial highlights (revenue of $868 million, net loss of $171 million, adjusted EBITDA of $73 million), segment performance, balance sheet metrics, and forward guidance for Q3 2026. This is a standard quarterly earnings release that would materially affect a reasonable investor's assessment of the company's financial condition and performance.
View raw filing on EDGAR →The audit committee concluded that previously issued financial statements for multiple periods (fiscal years 2024–2025 and quarterly periods through Q1 2026) should no longer be relied upon due to unrecorded sales and income tax liabilities discovered in a nexus study. The Company plans to restate these financial statements and has identified a material weakness in internal controls over tax compliance. This is a classic restatement disclosure under Item 4.02, with quantified preliminary adjustments (~$1.98 million in liabilities) affecting multiple line items.
View raw filing on EDGAR →Grace Therapeutics entered into a securities purchase agreement on August 4, 2026, to issue 4,761,904 shares of common stock at $2.10 per share in a private placement offering, generating approximately $10 million in gross proceeds. The unregistered securities were sold under Section 4(a)(2) of the Securities Act and Rule 506, with 90-day lock-up restrictions, representing a material dilutive issuance to raise capital for the company's operations.
View raw filing on EDGAR →SIGA Technologies issued a press release on August 6, 2026, announcing financial results for the quarter and six months ended June 30, 2026. The disclosure includes detailed financial statements (balance sheet, income statement), revenue figures ($37.9M product sales in Q2 2026), net income ($12.5M), and diluted EPS ($0.17), along with operational highlights regarding TPOXX product deliveries. This is a standard quarterly earnings release furnished under Item 2.02 of Form 8-K.
View raw filing on EDGAR →This exhibit is a press release announcing Seanergy's second quarter and first-half 2026 financial results, including record Q2 net income of $26.2 million and adjusted EPS of $1.32. The document presents comprehensive financial tables, reconciliations of non-GAAP measures, and management commentary on operational performance. While the release also discusses capital allocation (dividends, fleet renewal, and debt issuance), the primary disclosure is the quarterly and interim financial results, which is the hallmark of an earnings_release.
View raw filing on EDGAR →SUI Group Holdings issued a press release on August 6, 2026, announcing its financial results for the fiscal second quarter ended June 30, 2026. The disclosure includes Q2 2026 financial summary with total revenue, net loss, and treasury updates, along with operational highlights. This is a standard earnings release furnished as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition), which is material to investors assessing the company's financial performance and digital asset treasury strategy.
View raw filing on EDGAR →Item 2.02 discloses Magnera's third-quarter financial results for the period ended June 27, 2026, with a press release attached as Exhibit 99.1. The release reports GAAP net sales of $857 million, operating income of $22 million, and adjusted EBITDA of $99 million, along with detailed segment performance and cash flow metrics. This is a standard quarterly earnings disclosure material to investors assessing the company's operational and financial performance.
View raw filing on EDGAR →AMN Healthcare disclosed its second quarter 2026 financial results on August 6, 2026, reporting consolidated revenue of $673.2 million, net income of $21.2 million ($0.53 per diluted share), and adjusted EBITDA of $73.4 million. The press release, furnished as Exhibit 99.1, presents comprehensive quarterly financial results including segment performance, margin analysis, cash position, and forward guidance for Q3 2026. This is a standard earnings release disclosure under Item 2.02.
View raw filing on EDGAR →Halozyme issued a press release on August 6, 2026, reporting financial results for Q2 2026 ended June 30, 2026, disclosing total revenue of $481 million (48% YOY growth), royalty revenue of $308 million (50% YOY growth), and raising full-year 2026 financial guidance across multiple metrics including total revenue, royalty revenue, adjusted EBITDA, and non-GAAP diluted EPS. This is a standard quarterly earnings release furnished under Item 2.02.
View raw filing on EDGAR →ConocoPhillips issued a press release on August 6, 2026, announcing second-quarter 2026 financial and operating results, including reported earnings per share of $3.23 and adjusted EPS of $3.24, cash from operations of $7.2 billion, and production metrics. The disclosure is a standard quarterly earnings announcement with comparative year-over-year results and forward guidance, clearly fitting the earnings_release category under Item 2.02.
View raw filing on EDGAR →Westwood Holdings Group announced its second quarter 2026 financial results on August 6, 2026, disclosing quarterly revenues of $25.3 million, net income of $1.5 million, and diluted EPS of $0.17, along with comprehensive financial statements and non-GAAP metrics.
View raw filing on EDGAR →This Item 5.07 disclosure reports the results of Commvault's Annual Meeting of Stockholders held on August 6, 2026, including voting outcomes on four matters: election of seven directors, advisory vote on executive compensation, ratification of Ernst & Young LLP as independent auditor, and approval of the 2026 Equity Plan with 3.374 million shares. The detailed vote tallies (For, Against, Abstain, Broker Non-Vote) for each director and proposal are the core content, making this a textbook shareholder vote results disclosure.
View raw filing on EDGAR →The press release announces a declared dividend of US$0.72 per common share (approximately US$60.42 million in total) and US$0.24 per BDR, with a record date of August 18, 2026 and payment date of August 28, 2026. This is a material capital distribution to shareholders that would affect a reasonable investor's assessment of the company's capital allocation and shareholder returns policy.
View raw filing on EDGAR →This is a press release announcing Equinox Gold's Q2 2026 financial and operating results, including revenue of $769.8 million, net income of $230.6 million, and gold production of 176,836 ounces. The release discloses quarterly financial statements and MD&A, making it a classic earnings release. The disclosure is material as it reports significant financial performance and includes updated 2026 production guidance reflecting the completed Orla Mining merger.
View raw filing on EDGAR →This is a press release disclosing Brookfield Asset Management's quarterly financial results for Q2 2026, including fee-related earnings of $808 million (up 20% YoY), distributable earnings of $707 million (up 15% YoY), and record fundraising of $77 billion. The filing explicitly states "On August 5, 2026, the Registrant issued a press release" under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings releases. The disclosure includes detailed financial statements, operating results by business segment, and forward guidance ("we expect our best year ever"), all hallmarks of a material quarterly earnings announcement.
View raw filing on EDGAR →This is a press release announcing Trekor Metals' second quarter 2026 financial results, including Adjusted EBITDA of $125 million, net income of $22.2 million ($0.06 per share), and operational metrics for Gibraltar and Florence Copper mines. The disclosure includes detailed financial tables, production data, and forward guidance, consistent with a quarterly earnings release.
View raw filing on EDGAR →The Audit Committee concluded on August 3, 2026 that "certain errors had been identified" in the Company's audited consolidated financial statements for fiscal year ended March 31, 2026, and determined that the Affected Financial Statements "require restatement." The errors are described as "quantitatively material" under IAS 8 and SEC SAB Nos. 99 and 108. The Company is filing Amendment No. 2 to the 2026 Annual Report on Form 20-F/A with restated audited consolidated financial statements, which is the hallmark of a financial restatement disclosure.
View raw filing on EDGAR →This is a press release announcing Himax's Q2 2026 financial results, including revenues of $227.4 million, gross margin of 33.1%, and earnings per diluted ADS of 11.4 cents—all exceeding prior guidance. The release also provides Q3 2026 guidance. This is a classic earnings_release disclosure, material to investors assessing the company's financial performance and forward outlook.
View raw filing on EDGAR →Aspen Aerogels announced Q2 2026 financial results on August 6, 2026, reporting total revenue of $49.8 million, net loss of $23.3 million, and adjusted EBITDA of $(6.6) million, along with forward guidance for Q3 2026 revenue of $65–$80 million and adjusted EBITDA of $7–$15 million.
View raw filing on EDGAR →This press release announces S&P Global Ratings' upgrade of Kinross' long-term issuer credit rating from 'BBB-' to 'BBB' with a stable outlook. While a credit rating upgrade is a positive governance/financial signal reflecting improved creditworthiness and balance sheet strength (net cash of $1.9 billion, total liquidity of $4.4 billion), it does not fit neatly into the specific event-type taxonomy. The upgrade is material to investors as it affects the company's cost of capital and financial standing, but it is neither a discrete financial event (debt issuance, impairment, covenant breach) nor a governance action (executive change, shareholder vote). It is best classified as a governance-related disclosure that does not fit a named category.
View raw filing on EDGAR →Compass Therapeutics issued a press release on August 6, 2026, announcing financial results for the quarter and six months ended June 30, 2026, including net loss, R&D and G&A expenses, and cash position. The filing explicitly states "On August 6, 2026, Compass Therapeutics, Inc. issued a press release announcing financial results for the quarter and six months ended June 30, 2026," with consolidated financial statements (income statement and balance sheet) attached as Exhibit 99.1. This is a standard quarterly earnings release disclosure under Item 2.02.
View raw filing on EDGAR →This press release announces Electra's response to a U.S. Department of Commerce rule restricting exports of battery black mass under the Defense Production Act. The disclosure is primarily operational and strategic in nature—it discusses how the new regulatory environment supports Electra's strategy to develop U.S. refining capacity for nickel and recycled battery materials, and notes the company's intent to participate in the 90-day public comment process. While the rule itself is regulatory, the company's substantive disclosure focuses on strategic positioning and business implications rather than a discrete legal or regulatory event affecting the company directly. This is material because it describes a policy development that directly supports the company's core business strategy and could affect the economic case for its proposed U.S. nickel refinery.
View raw filing on EDGAR →This is a standard earnings release disclosing Q2 2026 financial results for Aligos Therapeutics, including condensed consolidated statements of operations and balance sheets, net loss per share of $(0.14), and R&D/G&A expense details. The filing is made under Item 2.02 (Results of Operations and Financial Condition) with the press release attached as Exhibit 99.1, which is the typical structure for quarterly earnings disclosures. Material to investors as it provides current financial position and operational performance metrics.
View raw filing on EDGAR →This exhibit is a presentation of Q2 2026 financial results for Aura Minerals Inc., dated August 6, 2026. It discloses quarterly production (75k GEO), net revenues (US$336M), adjusted EBITDA (US$197M), net income (US$218M), and cash flow metrics, along with operational highlights and guidance. The document explicitly states "Second Quarter 2026 Presentation of Financial Results" and contains consolidated financial summaries typical of an earnings release.
View raw filing on EDGAR →Celldex issued a press release on August 6, 2026 announcing its financial results for the second quarter of 2026, including consolidated statements of operations and balance sheet data. The disclosure includes quarterly revenues ($22K), operating expenses ($80.6M), net loss ($73.5M), and loss per share ($0.94), along with cash position ($717.6M) and forward-looking guidance that cash is sufficient through 2028. This is a standard earnings release disclosure under Item 2.02.
View raw filing on EDGAR →This is a clear earnings release disclosing Corvus Pharmaceuticals' financial results for Q2 2026 (three and six months ended June 30, 2026), including net loss of $18.0 million for Q2 2026, R&D expenses of $16.0 million, and cash position of $215.2 million as of June 30, 2026. The press release is furnished as Exhibit 99.1 and filed under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings releases. The disclosure includes both financial results and a business update on clinical trial progress, which is typical for clinical-stage biopharmaceutical companies.
View raw filing on EDGAR →The 6-K discloses compensation arrangements approved by the Compensation Committee for Alan Bash in his newly appointed role as Interim Chief Executive Officer, including bi-weekly cash compensation of $12,019 (effective July 27, 2026) and a one-time RSU grant valued at $50,000 vesting over three years. This is a material executive compensation disclosure under Item 5.02(e) equivalent, as it involves a named executive's compensatory arrangement in connection with a significant leadership role.
View raw filing on EDGAR →AvePoint issued a press release on August 6, 2026 announcing its financial results for the second quarter ended June 30, 2026, disclosing Q2 2026 revenue of $124.5 million (22% YoY growth), SaaS revenue of $98.5 million (27% YoY growth), ARR of $465.1 million (27% YoY growth), and updated full-year 2026 guidance. The filing explicitly states this is Item 2.02 (Results of Operations and Financial Condition) with the press release attached as Exhibit 99.1, which is the standard format for earnings releases.
View raw filing on EDGAR →